Who
Brian T. Crum
SVP, General Counsel & Secr.
Company insider
Files Form 4 as: SVP, General Counsel & Secr., Lexicon Pharmaceuticals.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Feb 2020
- Last trade
- 28 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —33,457 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —69,386 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —170,163 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —69,386 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,457 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —170,163 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $154K105,019 at $1.47 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —69,386 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,457 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —170,163 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —33,457 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —69,386 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —170,163 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $154K105,019 at $1.47 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —299,710 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —449,560 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —299,710 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —449,560 at $0.00 | filing |
| 28 Feb 2025filed 3 Mar 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —26,097 | filing |
| 28 Feb 2025filed 3 Mar 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,456 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.